Schizophrenia and Schizophrenia-Like Psychosis

Neurology and Clinical Neuroscience

Volumn , Issue , 2007, Pages 223-233

  Price, Gary ^a,b   Ron, Maria A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857566183     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03354-1.50022-5     Document Type: Chapter

References (148)

1. Harrison PJ The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122:593-624.
2. Harrison PJ, Weinberger DR Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68.
3. Joyce E, Huddy V Defining the cognitive impairment in schizophrenia. Psychol Med 2004, 34:1151-1155.
4. Shenton ME, Dickey CC, Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
5. Rapoport JL, Giedd JN, Blumenthal J, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 1999, 56:649-654.
6. Knapp M, Mangalore R, Simon J The global costs of schizophrenia. Schizophr Bull 2004, 30:279-293.
7. Kraeplin E Psychiatrie. Ein Lehrbuch für Studirende und Aerzte. Fünfte, vollständig umgearbeitete Auflage 1896, Barth Verlag, Leipzig.
8. Bleuler E Dementia praecox oder die Gruppe der Schizofrenien. Handbuch der Psychiatrie 1911-1928, G. Aschaffenburg, Leipzig. G. Aschaffenburg (Ed.).
9. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization, Geneva.
10. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
11. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992, 20:1-97.
12. Harrison G, Glazebrook C, Brewin J, et al. Increased incidence of psychotic disorders in migrants from the Caribbean to the United Kingdom. Psychol Med 1997, 27:799-806.
13. Nimgaonkar VL, Fujiwara TM, Dutta M, et al. Low prevalence of psychoses among the Hutterites, an isolated religious community. Am J Psychiatry 2000, 157:1065-1070.
14. Hafner H, Hambrecht M, Loffler W, et al. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle. Psychol Med 1998, 28:351-365.
15. Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995, 378:176-179.
16. Shergill SS, Brammer MJ, Williams SC, et al. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 2000, 57:1033-1038.
17. Hafner H, Maurer K, Loffler W, et al. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993, 162:80-86.
18. Arndt S, Andreasen NC, Flaum M, et al. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry 1995, 52:352-360.
19. Fenton WS, McGlashan TH Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992, 49:179-184.
20. Davidson L, McGlashan TH The varied outcomes of schizophrenia. Can J Psychiatry 1997, 42:34-43.
21. Harrison PJ, Eastwood SL Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 2001, 11:508-519.
22. Suvisaari JM, Haukka J, Tanskanen A, et al. Age at onset and outcome in schizophrenia are related to the degree of familial loading. Br J Psychiatry 1998, 173:494-500.
23. Gold S, Arndt S, Nopoulos P, et al. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 1999, 156:1342-1348.
24. Bilder RM, Lipschutz-Broch L, Reiter G, et al. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992, 18:437-448.
25. Hoff AL, Riordan H, O'Donnell DW, et al. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 1992, 149:898-903.
26. Joyce E, Hutton S, Mutsatsa S, et al. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry Suppl 2002, 43:s38-s44.
27. Weickert TW, Goldberg TE, Gold JM, et al. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000, 57:907-913.
28. Fuller R, Nopoulos P, Arndt S, et al. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002, 159:1183-1189.
29. Joyce E, Huddy V Defining the cognitive impairment in schizophrenia. Psychol Med 2004, 34:1151-1155.
30. Townsend LA, Malla AK, Norman RM Cognitive functioning in stabilized first-episode psychosis patients. Psychiatry Res 2001, 104:119-131.
31. Addington J, Brooks BL, Addington D Cognitive functioning in first episode psychosis: initial presentation. Schizophr Res 2003, 62:59-64.
32. Dickinson D, Iannone VN, Wilk CM, et al. General and specific cognitive deficits in schizophrenia. Biol Psychiatry 2004, 55:826-833.
33. Goldstein G, Shemansky WJ Influences on cognitive heterogeneity in schizophrenia. Schizophr Res 1995, 18:59-69.
34. Tuulio-Henriksson A, Partonen T, Suvisaari J, et al. Age at onset and cognitive functioning in schizophrenia. Br J Psychiatry 2004, 185:215-219.
35. Glahn DC, Therman S, Manninen M, et al. Spatial working memory as an endophenotype for schizophrenia. Biol Psychiatry 2003, 53:624-626.
36. Weinberger DR, Lipska BK Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995, 16:87-110.
37. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002, 5:267-271.
38. Volz HP, Gaser C, Hager F, et al. Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test-a functional MRI study on healthy volunteers and schizophrenics. Psychiatry Res 1997, 75:145-157.
39. Gallhofer B, Lis S, Meyer-Lindenberg A, et al. Cognitive dys-function in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr Scand Suppl 1999, 395:118-128.
40. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25:201-222.
41. Cardno AG, Gottesman II Twin studies of schizophrenia: from bow-and-arrow concordances to Star Wars Mx and functional genomics. Am J Med Genet 2000, 97:12-17.
42. Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999, 56:162-168.
43. Gershon ES, DeLisi LE, Hamovit J, et al. A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1988, 45:328-336.
44. Kendler KS, MacLean CJ Estimating familial effects on age at onset and liability to schizophrenia. I. Results of a large sample family study. Genet Epidemiol 1990, 7:409-417.
45. Driscoll DA, Spinner NB, Budarf ML, et al. Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome. Am J Med Genet 1992, 44:261-268.
46. Murphy KC, Jones LA, Owen MJ High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999, 56:940-945.
47. Hodgkinson CA, Goldman D, Jaeger J, et al. Disrupted in schizophrenia 1: association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 2004, 75:862-872.
48. Harrison PJ, Owen MJ Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003, 361:417-419.
49. Harrison PJ, Weinberger DR Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68.
50. Lawrie SM, Whalley H, Kestelman JN, et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 1999, 353:30-33.
51. Shenton ME, Dickey CC, Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
52. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000, 157:16-25.
53. Foong J, Symms MR, Barker GJ, et al. Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. Brain 2001, 124:882-892.
54. Bagary MS, Symms MR, Barker GJ, et al. Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch Gen Psychiatry 2003, 60:779-788.
55. Gur RE, Turetsky BI, Cowell PE, et al. Temporolimbic volume reductions in schizophrenia. Arch Gen Psychiatry 2000, 57:769-775.
56. McIntosh AM, Job DE, Moorhead TW, et al. Voxel-based morphometry of patients with schizophrenia or bipolar disorder and their unaffected relatives. Biol Psychiatry 2004, 56:544-552.
57. Blennow K, Davidsson P, Gottfries C-G, et al. Synaptic degeneration in thalamus in schizophrenia [Letter]. Lancet 1996, 348:692-693.
58. Maier M, Ron MA, Barker GJ, et al. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med 1995, 25:1201-1209.
59. Bertolino A, Roffman JL, Lipska BK, et al. Reduced N-acetylaspartate in prefrontal cortex of adult rats with neonatal hippocampal damage. Cereb Cortex 2002, 12:983-990.
60. Byne W, Buchsbaum MS, Kemether E, et al. Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psychiatry 2001, 58:133-140.
61. Uranova NA, Vostrikov VM, Orlovskaya DD, et al. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004, 67:269-275.
62. Rapoport JL, Giedd JN, Blumenthal J, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 1999, 56:649-654.
63. Foong J, Maier M, Clark CA, et al. Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry 2000, 68:242-244.
64. Price G, Bagary MS, Cercignani M, et al. The corpus callosum in first episode schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry 2005, 76:585-587.
65. Arnold SE, Trojanowski JQ, Gur RE, et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998, 55:225-232.
66. Purohit DP, Perl DP, Haroutunian V, et al. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 1998, 55:205-211.
67. Falke E, Han LY, Arnold SE Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res 2000, 93:103-110.
68. Harrison PJ The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122:593-624.
69. Torrey EF, Miller J, Rawlings R, et al. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997, 28:1-38.
70. Wright P, Takei N, Rifkin L, et al. Maternal influenza, obstetric complications, and schizophrenia. Am J Psychiatry 1995, 152:1714-1720.
71. Brown AS, Begg MD, Gravenstein S, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Obstet Gynecol Surv 2005, 60:77-78.
72. Cannon M, Jones PB, Murray RM Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 2002, 159:1080-1092.
73. Carlsson A, Lindqvist M Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963, 20:140-144.
74. Creese I, Burt DR, Snyder SH Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
75. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
76. Luby ED, Cohen BD, Rosenbaum G, et al. Study of a new schizophrenomimetic drug: sernyl. AMA Arch Neurol Psychiatry 1959, 81:363-369.
77. Javitt DC, Zukin SR Recent advances in the phencyclidine model of schizophrenia [Review]. Am J Psychiatry 1991, 148:1301-1308.
78. Carlsson M, Carlsson A Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990, 13:272-274.
79. Benes FM, Berretta S GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25:1-27.
80. Reynolds GP, Beasley CL, Zhang ZJ Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J Neural Transm 2002, 109:881-889.
81. Gouzoulis-Mayfrank E, Hermle L, Thelen B, et al. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 1998, 31(Suppl 2):63-68.
82. Meltzer HY, Matsubara S, Lee JC Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J Pharmacol Exp Ther 1989, 251:238-246.
83. Weinberger DR, McClure RK Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?. Arch Gen Psychiatry 2002, 59:553-558.
84. Seeman P Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992, 7:261-284.
85. Keshavan MS, Haas GL, Kahn CE, et al. Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible?. J Psychiatr Res 1998, 32:161-167.
86. Hawkins KA, Mohamed S, Woods SW Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?. Psychol Med 1999, 29:1-8.
87. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992, 49:538-544.
88. Casey DE Dopamine D1 (and D2 [haloperidol]) antagonists in drug-naïve monkeys. Psychopharmacology (Berl) 1992, 107:18-22.
89. Klawans HL, Rubovits R An experimental model of tardive dyskinesia. J Neural Transm 1972, 33:235-246.
90. Gunne LM, Haggstrom JE Pathophysiology of tardive dyskinesia. Psychopharmacology Suppl 1985, 2:191-193.
91. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995, 52:756-765.
92. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association 1992, American Psychiatric Association, Washington, DC.
93. Gelenberg AJ, Bellinghausen B, Wojcik JD, et al. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 1988, 145:517-518.
94. Keck PE, Sebastianelli J, Pope HG, et al. Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J Clin Psychiatry 1989, 50:352-355.
95. Adnet P, Lesteval P, Krivosic-Horber R Neuroleptic malignant syndrome. Br J Anaesth 2000, 85:129-135.
96. Ames D, Wirshing W Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome: a possible link?. JAMA 1993, 269:869.
97. Sachdev P, Mason C, Hadzi-Pavlovic D Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997, 154:1156-1158.
98. Addonizio G, Susman VL, Roth SD Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987, 22:1004-1020.
99. Levinson DF, Simpson GM Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the "neuroleptic malignant syndrome.". Arch Gen Psychiatry 1986, 43:839-848.
100. Pelonero AL, Levenson JL, Pandurangi AK Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998, 49:1163-1172.
101. Gilbert P, Harris MJ, McAdams LA Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995, 52:173-188.
102. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003, 160:1209-1222.
103. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
104. Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999, 156:1744-1750.
105. Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999, 156:990-999.
106. Seeman P, Tallerico T Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998, 3:123-134.
107. Reynolds GP Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004, 18:340-345.
108. Wooltorton E Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002, 167:1269-1270.
109. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20:612-627.
110. Taylor DM Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 2003, 57:49-54.
111. Heresco-Levy U N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int J Neuropsychopharmacol 2000, 3:243-258.
112. Wyatt RJ, Henter ID The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res 1998, 3:169-177.
113. Gould RA, Mueser KT, Bolton E, et al. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophr Res 2001, 48:335-342.
114. Sensky T, Turkington D, Kingdon D, et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000, 57:165-172.
115. McGorry P, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with sub-threshold symptoms. Arch Gen Psychiatry 2002, 59:921-928.
116. Vaughn CE, Leff JP The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976, 129:125-137.
117. Pitschel-Walz G, Leucht S, Bauml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia-a meta-analysis. Schizophr Bull 2001, 27:73-92.
118. Bond GR, Becker DR, Drake RE, et al. Implementing supported employment as an evidence-based practice. Psychiatr Serv 2001, 52:313-322.
119. Slater E, Beard AW, Glithero E The schizophrenia-like psychosis of epilepsy. Br J Psychiatry 1963, 109:95-105.
120. Davidson K, Bagley CR Schizophrenia-like psychosis associated with organic disorders of the central nervous system: a review of the literature. Current Problems in Neuropsychiatry. British Journal of Psychiatry Special Publication No. 4 1969, Hedley Brothers, Ashford, Kent, UK. R.N. Herrington (Ed.).
121. Feinstein A, Ron MA Psychosis associated with demonstrable brain disease. Psychol Med 1990, 20:793-803.
122. Cummings JL Organic psychosis [Review]. Psychosomatics 1988, 29:16-26.
123. Johnstone EC, Cooling NJ, Frith CD, et al. Phenomenology of organic and functional psychoses and the overlap between them. Br J Psychiatry 1988, 153:770-776.
124. Toone BK, Garralda EM, Ron MA The psychosis of epilepsy and the functional psychosis. A clinical and phenomenological evaluation. Br J Psychiatry 1982, 141:256-261.
125. Sachdev P Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998, 155:325-336.
126. Gaitatzis A, Trimble MR, Sander JW The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004, 110:207-220.
127. Wolf P, Trimble MR Biological antagonism and epileptic psychosis. Br J Psychiatry 1985, 146:272-276.
128. Dongier S Statistical study of clinical and electroencephalographic manifestations of 536 psychotic episodes occurring in 516 epileptics between clinical seizures. Epilepsia 1959, 1:117-142.
129. Torta R, Keller R Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999, 40(Suppl 10):S2-S20.
130. Logsdail SJ, Toone BK Post-ictal psychoses. A clinical and phenomenological description. Br J Psychiatry 1988, 152:246-252.
131. Nathaniel-James DA, Brown RG, Maier M, et al. Cognitive abnormalities in schizophrenia and schizophrenia-like psychosis of epilepsy. J Neuropsychiatry Clin Neurosci 2004, 16:472-479.
132. Landolt H Some clinical EEG correlations in epileptic psychoses (twilight states). EEG Clin Neurophysiol 1953, 5:121.
133. Kanner AM Psychosis of epilepsy: a neurologist's perspective. Epilepsy Behav 2000, 1:219-227.
134. Trimble MR The Psychoses of Epilepsy 1991, Raven Press, New York.
135. Toone BK The psychoses of epilepsy. J Neurol Neurosurg Psychiatry 2000, 69:1-4.
136. Reutens DC, Savard G, Andermann F, et al. Results of surgical treatment in temporal lobe epilepsy with chronic psychosis. Brain 1997, 120:1929-1936.
137. Sánchez-Ramos JR, Ortoll R, Paulson GW Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996, 53:1265-1268.
138. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000, 123:733-745.
139. Burn DJ, Troster AI Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr Psychiatry Neurol 2004, 17:172-180.
140. Wint DP, Okun MS, Fernandez HH Psychosis in Parkinson's disease. J Geriatr Psychiatry Neurol 2004, 17:127-136.
141. Friedman JH, Factor SA Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000, 15:201-211.
142. Wilcox JA, Nasrallah HA Childhood head trauma and psychosis. Psychiatry Res 1987, 21:303-306.
143. Sachdev P, Smith JS, Cathcart S Schizophrenia-like psychosis following traumatic brain injury: a chart-based descriptive and case-control study. Psychol Med 2001, 31:231-239.
144. Fujii DE, Ahmed I Risk factors in psychosis secondary to traumatic brain injury. J Neuropsychiatry Clin Neurosci 2001, 13:61-69.
145. Feinstein A, du Boulay G, Ron MA Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry 1992, 161:680-685.
146. Black DN, Taber KH, Hurley RA Metachromatic leukodystrophy: a model for the study of psychosis. J Neuropsychiatry Clin Neurosci 2003, 15:289-293.
147. Hyde TM, Ziegler JC, Weinberger DR Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992, 49:401-406.
148. Ron MA, Feinstein A Multiple sclerosis and the mind. J Neurol Neurosurg Psychiatry 1992, 55:1-3.